Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug

Abstract

It has been noticed that Gallic acid can interfere with substantial pathways in different types of cancer, thus it was suggested to be a candidate for anticancer treatment. In this research, a new thought was tested to observe if Gallic acid would interfere to inhibit the glycolysis pathway. Inhibition of lactate dehydrogenase (LDH) by Gallic acid was tested using the normal human serum. The concentration of Gallic acid was ranged between 10–1 to 10–7 M, results indicated that the lowest and the highest concertation of Gallic acid were able to induce activity inhibition percentage between half and three quarters respectively. Furthermore, the anti-proliferation activity of Gallic acid against different types of cancer cells was tested in vitro using the MTT assay. these were the brain tumor glioblastoma (AMGM), skeletal muscle tumor rhabdomyosarcoma (RD), cervical cancer (HeLa), mice mammary gland adenocarcinoma cancer (AMN3) with two human breast cancers (AMJ13 and MCF7), and human ovarian cancer (SK-OV-3). Three concentrations were tested 10–1 10–2 and 10–3 M for three incubation times 24hr, 48hr, 72hr. The results indicated a profound growth inhibition activity with DNA fragmentation as an end event of apoptosis.